Full text

Turn on search term navigation

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Psoriasis is a chronic, inflammatory, multisystemic disease which affects approximately 2–3% of the population globally, whose onset is triggered by genetic and environmental factors which activate both dendritic cells and keratinocytes, resulting in the production of proinflammatory cytokines such as tumor necrosis factor alpha, interleukin 17, interleukin 23, interleukin 22, and interleukin 1β. An in-depth understanding of the pathophysiology of psoriasis led to significant advances in the development of safe and efficient novel therapeutic options, with four classes of biologic therapy being approved for the management of moderate to severe psoriasis: tumor necrosis factor alpha inhibitors, interleukin 23 inhibitors, anti-interleukin 12/23 agents, anti-interleukin 17 agents, as well as small-molecule inhibitors, such as apremilast. Psoriasis is associated with comorbid conditions, namely psoriatic arthritis, cardiovascular disease, metabolic syndrome, psychiatric disorders, malignancy, as well as inflammatory bowel disease. For patients affected by both psoriasis and inflammatory bowel disease, there is a strong recommendation to avoid IL-17 inhibitors since they may play a part in the exacerbation of the gastrointestinal disease. Our aim was to perform a thorough literature review regarding the development of inflammatory bowel disease lesions in psoriasis patients treated with IL-17 inhibitors, along with a case presentation to emphasize the need for close follow-up of these patients.

Details

Title
An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients
Author
Olguța Anca Orzan 1 ; Țieranu, Cristian George 2   VIAFID ORCID Logo  ; Olteanu, Andrei Ovidiu 2 ; Dorobanțu, Alexandra Maria 3   VIAFID ORCID Logo  ; Cojocaru, Anca 3 ; Mihai, Mara Mădălina 1   VIAFID ORCID Logo  ; Popa, Liliana Gabriela 1 ; Gheorghiu, Ana Maria 4 ; Giurcăneanu, Călin 1 ; Ion, Ana 3   VIAFID ORCID Logo 

 Department of Oncologic Dermatology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania; [email protected] (O.A.O.); [email protected] (L.G.P.); [email protected] (C.G.); Department of Dermatology, ‘Elias’ University Emergency Hospital, 011461 Bucharest, Romania; [email protected] (A.M.D.); [email protected] (A.C.); [email protected] (A.I.) 
 Department of Gastroenterology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania; [email protected]; Department of Gastroenterology, ‘Elias’ Emergency University Hospital, 011461 Bucharest, Romania 
 Department of Dermatology, ‘Elias’ University Emergency Hospital, 011461 Bucharest, Romania; [email protected] (A.M.D.); [email protected] (A.C.); [email protected] (A.I.) 
 Department of Rheumatology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania; [email protected]; Internal Medicine and Rheumatology, ‘Cantacuzino’ Hospital, 011438 Bucharest, Romania 
First page
2171
Publication year
2023
Publication date
2023
Publisher
MDPI AG
e-ISSN
19994923
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2857412813
Copyright
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.